Skip to main content
. 2019 Jun 6;11(12):1083–1094. doi: 10.1093/jmcb/mjz016

Figure 6.

Figure 6

Overexpression of CILP-2 using Ad-CILP-2 exacerbates insulin resistance in vivo and in vitro. (A) Experimental protocol for Ad-CILP-2 delivery and insertion of catheters and clamp protocol. (B) Glucose infusion rate (GIR). (C) Glucose disappearance rates (GRd). (D) Hepatic glucose production (HGP). (E) Percentage of the suppression of endogenous glucose production. (F) Whole-body glucose uptake. (G) HepG2 cells and MPHs were treated as indicated in Materials and methods. Western blots (left) and quantitative measurements of p-InsR, p-Akt, PEPCK, G6Pase, and CILP-2 protein (right). NC, standard chow diet; HFD, high-fat diet; MPH, mouse primary hepatocytes. Values are mean ± SEM (n = 5 for in vivo study). *P < 0.05, **P < 0.01 vs. Ad-GFP.